International Health Management Association

What International Health Management Association does

International Health Management Associates (IHMA) is a privately-held specialty contract research organization headquartered in Schaumburg, Illinois, founded in 1992. The company provides central, reference, and clinical research laboratory services dedicated exclusively to antimicrobial drug development, supporting pharmaceutical and biotechnology companies across all four phases of anti-infective therapy development: drug discovery, clinical development, regulatory submissions, and commercialization. Its service portfolio includes a Bacterial Repository for discovery-stage research, clinical scientific expertise consulting, specialized microbiology laboratory services, molecular characterization and detection of infectious agents, and antimicrobial resistance (AMR) surveillance covering bacterial and fungal pathogens. The company also supports novel therapeutic modalities such as bacteriophage and vaccine candidates, and has expanded into in vitro diagnostic device study support.

The company's technology platform is built on conventional microbiology laboratory capabilities rather than software or AI-driven systems, with proprietary programs such as the Antimicrobial Voluntary Evaluation Program (AVEP) and the Manufacturers Interface and Performance Program (MIPP) providing structured commercialization-phase services. Its competitive positioning rests on depth of domain specialization in anti-infectives, longevity in the field, and institutional memberships in standards-setting and AMR-focused organizations including CLSI, AMR Insights, and PACE. Global laboratory service coverage is claimed, though specific geographic footprint details are not disclosed.

IHMA's business model is project-based professional services delivered under B2B enterprise sales engagements with pharmaceutical, biotechnology, and diagnostic companies. Pricing is not publicly disclosed and is customized per protocol specifications. The go-to-market relies on direct enterprise sales and professional network channels rather than broad marketing, with no disclosed funding rounds, acquisitions, leadership changes, or expansion milestones in the available source material. Customer concentration cannot be assessed from the data provided, and there is no public revenue disclosure.

Name

International Health Management Association

Legal name

International Health Management Associates

Website

https://ihmainc.com

Company type

Private

Founded year

1992

Operating status

Operating

Headcount range

51–100 employees

Short description

IHMA is a privately-held specialty CRO founded in 1992 that provides central, reference, and clinical research microbiology laboratory services to pharmaceutical and biotechnology companies developing anti-infective therapies, covering all phases from drug discovery through commercialization globally.

Ownership category

akta.pro rank

Product category

Clinical Laboratory Services

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151)

SIC

Services-Medical Laboratories (8071), Services-Testing Laboratories (8734)

akta.pro primary industry

Microbiology & Infectious Disease Testing (Trial Support) (HLAGAEAF)

akta.pro secondary industries

Microbiology & Infectious Disease Testing Laboratories (HLAFAMAD), Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels) (HLAAALAC)

Keywords

• Clinical laboratory services
• Antimicrobial drug development
• Microbiology testing services
• Central laboratory services
• Antimicrobial resistance surveillance

Headquarters

HQ city

Schaumburg

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Laboratory Services: Project-based laboratory testing services for pharmaceutical and biotech companies across all phases of anti-infective drug development, from discovery through commercialization. Services include pre-clinical studies, clinical trial support, antimicrobial resistance surveillance, and specialized microbiology testing.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

IHMA provides central, reference, and clinical research microbiology laboratory services that support all phases of anti-infective therapy development, from drug discovery and pre-clinical studies through clinical development, regulatory submissions, and commercialization. Services are customized to align with per-protocol specifications and include bacterial repository access, AMR surveillance for bacterial and fungal pathogens, molecular characterization, central lab services for clinical trials, and specialized evaluation programs for manufacturers.

Product overview

IHMA offers a unified suite of microbiology laboratory and scientific services supporting all phases of antimicrobial drug development, from discovery through commercialization. The portfolio includes the Bacterial Repository for discovery research, Clinical Scientific Expertise providing consultation across all phases, Specialized Microbiology Laboratory Services deployed across four development stages (Drug Discovery, Clinical Development, Regulatory Submissions, and Commercialization), Central Laboratory Microbiology Services for clinical and regulatory phases, Antimicrobial Resistance Surveillance for bacterial and fungal pathogens, the Antimicrobial Voluntary Evaluation Program (AVEP) for commercialization support, and the Manufacturers Interface and Performance Program (MIPP) for manufacturer engagement. Services also include molecular characterization and detection of infectious agents, and in vitro diagnostic device study support.

Differentiator

Problem solved

Functional benefit

Products and services

• Bacterial Repository Repository services supporting antimicrobial drug discovery and research activities for pharmaceutical and biotechnology companies.
• Clinical Scientific Expertise Expert scientific consultation and support services for clinical development across all phases of antimicrobial drug development.
• Specialized Microbiology Laboratory Services Comprehensive microbiology testing services deployed across drug discovery, clinical development, regulatory submissions, and commercialization phases for anti-infective development.
• Central Laboratory Microbiology Services Central laboratory services providing microbiology expertise for clinical development and regulatory submission phases of anti-infective therapies.
• Antimicrobial Resistance Surveillance Surveillance services monitoring antimicrobial resistance patterns for bacterial and fungal pathogens, supporting regulatory submissions and commercialization activities.
• Antimicrobial Voluntary Evaluation Program (AVEP) Voluntary evaluation program supporting antimicrobial products during the commercialization phase, including performance evaluation services.
• Manufacturers Interface and Performance Program (MIPP) Program interface connecting manufacturers with performance evaluation services for antimicrobial products during commercialization.

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Three partnerships are on record, tiered minor.

• CLSI (Clinical and Laboratory Standards Institute)minorOthersIHMA is a member of CLSI, an organization that develops clinical laboratory testing standards. This membership provides access to standardized methodologies and positions IHMA within the clinical laboratory standards community.
• AMR InsightsminorStrategic or Co-development PartnerIHMA is a partner of AMR Insights, an organization focused on antimicrobial resistance. This partnership supports IHMA's antimicrobial resistance surveillance capabilities and positions the company within the AMR knowledge ecosystem.
• PACEminorOthersIHMA is associated with PACE organization. The nature of this partnership appears to be organizational/membership based, providing IHMA with connection to PACE's network and resources.

Scale indicators1 record

Recent moves5 records

Expansion highlights4 records

Direct peers

• Eurofins Scientific: Global contract laboratory with extensive microbiology and antimicrobial testing capabilities for pharmaceutical and clinical trial sponsors. Eurofins is a direct competitor in central/reference microbiology lab services and offers comparable scale and geographic reach to IHMA.
• Charles River Laboratories: Preclinical and clinical laboratory services provider with a dedicated anti-infective and microbiology practice supporting drug development. Directly comparable in serving the same pharma/biotech sponsors developing anti-infectives, particularly in preclinical and clinical phases.
• Microbiologics: Provider of biological reference materials, microbial strains, and quality control organisms used in antimicrobial and infectious disease research. Directly comparable to IHMA's Bacterial Repository service line for discovery and surveillance customers.
• ATCC: Global biological resource center supplying authenticated microbial strains and reference cultures to pharma, biotech, and public health researchers. Overlaps directly with IHMA's Bacterial Repository capability and antimicrobial discovery support.

Broad incumbents

• Labcorp Drug Development (Fortrea): Large central laboratory services provider supporting global clinical trials with broad microbiology and infectious disease testing capabilities. Represents a scaled incumbent competing for the same central lab and clinical trial microbiology work that IHMA performs.
• IQVIA: Global CRO and central laboratory operator offering microbiology and clinical trial lab services as part of an integrated drug development platform. Competes with IHMA on bundled offerings and global trial support.
• ICON plc: Major central laboratory and CRO with microbiology testing capabilities serving clinical trial sponsors across therapeutic areas. Comparable as a scaled central lab competitor targeting the same pharma/biotech customer base.
• Thermo Fisher Scientific (Microbiology & Pharma Services): Diversified life sciences company with microbiology products, clinical trial lab services, and antimicrobial research offerings. Competes with IHMA across multiple service lines, including molecular characterization and diagnostic device studies.
• SGS: Global testing, inspection, and certification company with life sciences and clinical trial laboratory services including microbiology. Comparable as a large-scale lab services provider competing for clinical research and antimicrobial testing contracts.

Emerging players

• bioMérieux: In vitro diagnostics and microbiology company providing antimicrobial susceptibility testing and surveillance solutions. Comparable to IHMA in the AMR surveillance and microbiology diagnostics space, though more diagnostic-product-oriented.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/_ihma_

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about International Health Management Association